Last updated: Nov 10, 2025
While the outcome of the US presidential election is drawing most of the political attention these days, other political activity in Europe merits serious attention as well. Pharma reform legislation is moving forward in the EU that could significantly change everything from how firms manufacture their products to how much market exclusivity they get for them. These Pink Sheet stories break down the key issues, explaining what is already basically set and what remains undecided in this major initiative.
Related product
OCT 30, 2024
Article
薬事規制関連支援サービス
Artificial Intelligence Regulation
Drug sponsors strive to make the best use of artificial intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from the US, Europe, and Asia of the emerging framework for AI regulation.
